Hepatic metastases from carcinomas of unknown primary site: Experience of the montpellier cancer center

Gastroenterologie Clinique et Biologique

Volumn 29, Issue 12, 2005, Pages 1224-1232

  Pouessel, Damien ^a   Thezenas, Simon ^a   Culine, Stéphane ^a   Becht, Catherine ^a   Senesse, Pierre ^a   Ychou, Marc ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ELVORINE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BONE METASTASIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOMA; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG FATALITY; FEMALE; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; PERFORMANCE; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

EID: 31644440087     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(05)82205-5     Document Type: Article

References (27)

1. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993;329:257-63.
2. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 1992;10:912-22.
3. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4:53-58.
4. Van der Gaast A, Verweij J, Planting AST, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995;13:1720-25.
5. Abbruzzese JL, Abbruzzese MC, Hess BCR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 patients. J Clin Oncol 1994;12:1272-80.
6. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients withn suspected tumors of unknown origin. J Clin Oncol 1995;13:2094-103.
7. Lesimple T, Voigt JJ, Bataillard A, Coindre JM, Culine S, Lortholary A, et al. Recommandations pour la pratique clinique : Standards, Options et Recommandations 2002 pour le diagnostic des carcinomes de site primitif inconnu. Bull Cancer 2003;90:1071-96.
8. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, et al. Summary of the Standards, Options, and Recommendations for the management of patient with carcinoma of unknown primary site (2002). Br J Cancer 2003;89(suppl 1): S59-66.
9. Sporn JR, Greenberg BR. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol 1993;20:261-67.
10. Mousseau M, Schaerer R, Lutz JM, Ménégoz F, Faure H, Swiercz P. Métastases hépatiques de site primitif inconnu. Bull Cancer 1991;78:725-36.
11. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 1998;16:2105-12.
12. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002;20:4679-83.
13. Khambhu SA, Kelsen DP, Fiore J, Niedzwiecki D, Chapman D, Vinciguerra V, et al. Metastatic adenocarcinomas of unknown primary site. Am J Clin Oncol 1990;13:55-60.
14. Al-Idrissi HY. Combined 5-fluorouracil, adriamycin and mitomycin-C in the management of adenocarcinoma metastazing to the liver from unknown primary site. J Int Med Res 1990;18:425-29.
15. Miller AB, Hoogstraten B, Staquet B, Winkler A. Reporting results of cancer. Cancer 1981;47:207-14.
16. Culine S, Gazagne L, Ychou M, Romieu G, Fabbro M, Cupissol D, et al. Les carcinomes de primitif inconnu. A propos de 100 patients traités au Centre Régional de Lutte contre le Cancer de Montpellier. Rev Med Int 1998;19:713-29.
17. Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O'Kelly P, et al. Hepatic metastases from an unknown primary neoplasm: survival, prognostic indicators and value of extensive investigations. Clinical Radiology 2002 ;57:1073-77.
18. Fizazi K, Culine S. Les carcinomes métastatiques d'origine indéterminée. Bull Cancer 1998;85:609-17.
19. Lortholary A, Abadie-Lacourtoisie S, Guerin O, Mege M, Rauglaudre GD, Gamelin E. Cancers d'origine indéterminée: A propos de 311 cas. Bull Cancer 2001;88:619-27.
20. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown primary carcinoma? J Clin Oncol 1997;15:2056-66.
21. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol 1987;10:82-5.
22. Milliken ST, Tattersall MHN, Woods RL, Coates AS, Levi JA, Fox RM, et al. Metastatic adenocarcinoma of unknown primary site: A randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987;23:1645-50.
23. Falkson CI, Cohen GL. Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998;55:116-121.
24. Culine S, Ychou M, Fabbro M, Romieu G, Cupissol D. 5-Fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001;21:1455-58.
25. Hainsworth JD, Burris HA, Greco FA. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001;19:335-9.
26. Pouessel D, Culine S, Becht C, Romieu G, Fabbro M, Ychou M, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003;23:2801-04.
27. Fizazi K, Voigt JJ, Lesimple T, Lortholary R, Bugat R, Merrouche Y, et al. Carcinoma of unknown primary: Are the tyrosine kinase receptors HER-2, EGF-R, and c-Kit suitable targets for therapy? [abstract]. Proc Am Soc Clin Oncol 2003;22: 3549.